EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*

Kempf, Werner; Pfaltz, Katrin; Vermeer, Maarten H.; Cozzio, Antonio; Ortiz‐Romero, Pablo L.; Bagot, M.; Olsen, Elise A.; Kim, Youn H.; Dummer, Reinhard; Pimpinelli, Nicola; Whittaker, Sean; Hodak, Emmilia; Cerroni, Lorenzo; Berti, Emilio; Horwitz, Steve; Prince, H. Miles; Guitart, Joan; Estrach, Teresa; Sanches, José Antônio; Duvic, Madeleine; Ranki, Annamari; Dréno, Brigitte; Ostheeren-Michaelis, Sonja; Knobler, Robert; Wood, Gary S.; Willemze, Rein

doi:10.1182/blood-2011-05-351346

Cited by 363 publications

(499 citation statements)

References 105 publications

(99 reference statements)

Supporting

Mentioning

441

Contrasting

Unclassified

Order By: Relevance

“…El diagnóstico se realiza mediante biopsia de piel; ésta debe incluir hipodermis 1 . El análisis histológico mostrará infiltrado linfocítico dér-mico con células grandes anaplásticas, núcleo redondo-oval, irregular, indentado y nucléolo prominente.…”

Section: Discussionunclassified

“…La IHQ muestra un patrón CD3+, CD4+, CD8-, y CD30+. Por definición, CD30 debe expresarse en al menos 75% de las células linfoides grandes 1 . El antígeno ALK-1 (anaplastic lymphoma kinase) debe ser negativo.…”

Section: Discussionunclassified

“…Corresponden a un espectro de enfermedades que incluyen la papulosis linfomatoide y el linfoma anaplástico de células grandes primario cutáneo (LACGPC) 1,2 . El linfoma anaplástico de células grandes (LACG) ocurre como dos entidades clínicamente distintas: el LACGPC y el LACG nodal/sistémico.…”

unclassified

“…El LACGPC se manifiesta como tumores o placas ulceradas, de crecimiento rápido, en forma solitaria o agrupada y posee un excelente pronós-tico 1,2 . Su contraparte nodal/sistémica (LACG nodal) es un linfoma agresivo que requiere tratamiento con poliquimioterapia.…”

unclassified

“…Su contraparte nodal/sistémica (LACG nodal) es un linfoma agresivo que requiere tratamiento con poliquimioterapia. 1 …”

unclassified

See 4 more Smart Citations

Linfoma anaplástico de células grandes CD30 positivo cutáneo primario: reporte de un caso

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

unclassified

“…Su contraparte nodal/sistémica (LACG nodal) es un linfoma agresivo que requiere tratamiento con poliquimioterapia. 1 …”

unclassified

See 3 more Smart Citations

Linfoma anaplástico de células grandes CD30 positivo cutáneo primario: reporte de un caso

et al. 2015

View full text Add to dashboard Cite

show abstract

Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma

et al. 2015

View full text Add to dashboard Cite

Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare primary cutaneous CD30 + T-cell lymphoproliferative disorder that affects patients at a median age of 60 years. The disease presents as localized or less frequently disseminated nodules, plaques, or ulcers that mostly affect limbs. Prognosis is favorable (5-year overall survival, >80%). According to the consensus recommendations, 1 surgical excision or radiotherapy is recommended for localized lesions. For multifocal lesions, low-dose methotrexate is commonly used with a favorable response. 2 Multiagent chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, is effective but because of adverse effects and a high rate of relapses is reserved for disseminated relapse and extracutaneous dissemination. 1 Brentuximab vedotin has excellent effectiveness, 3 but its use remains off label, expensive, and sometimes responsible for neuropathy and severe infectious complications. Consequently, therapeutic recommendations are lacking for patients with methotrexate failure, especially for older patients. We report a series of 7 patients who received vinblastine as single-agent chemotherapy for relapsing multifocal C-ALCL.

show abstract